Ennui or not ennui, that is the question...

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 767-769

  Cheson, B D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BRYOSTATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; FENRETINIDE; FLUDARABINE; PACLITAXEL; PENTOSTATIN;

CLINICAL TRIAL; EDITORIAL; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0029957407     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010753     Document Type: Editorial

References (37)

1. Wilde O. The Picture of Dorian Gray (1881) 1995 Crescent Books New York The Complete Oscar Wilde
2. Yang E. Korsmeyer S.J. Molecular thanaptosis: A discourse on the bcl-2 family and cell death Blood 88 1996 386 401
3. Carson D.A. Wasson D.B. Esparza L.M. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-ara-bino-fluoro-2′-deoxyadenosine Proc Natl Acad Sci 89 1992 2970 2974
4. Robertson L.E. Chubb S. Meyn R.E. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl fluoroadenine Blood 81 1993 143 150
5. Piro L.D. Carrera C.J. Carson D.A. Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine N Engl J Med 322 1990 1117 1121
6. Grever M. Kopecky K. Foucar M.K. A randomized comparison of pentostatin vs. alpha-interferon in previously untreated patients with hairy cell leukemia: An intergroup study J Clin Oncol 13 1995 974 982
7. Keating M.J. O'Brien S. Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent Blood 81 1993 2878 2884
8. Rai K.R. Peterson B. Kolitz J. Fludarabine induces high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL) Blood 86 Suppl 1 1995 607a (Abstr 2414)
9. French Cooperative Group on CLL Johnson S. Smith A.G. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia Lancet 347 1996 1432 1438
10. Redman J.R. Cabanillas F. Velasquez W.S. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma J Clin Oncol 10 1992 790 794
11. Hochster H.S. Kim K. Green M.D. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study J Clin Oncol 10 1992 28 32
12. Hiddemann W. Unterhalt M. Pott C. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German low-grade Non-Hodgkin's Lymphoma Study Group Semin Oncol 20 Suppl 7 1993 28 31
13. Zinzani P.L. Lauria F. Rondelli D. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma Ann Oncol 4 1993 575 578
14. Pigaditou A. Rohatiner A.Z.S. Whelan J.S. Fludarabine in low-grade lymphoma Semin Oncol 20 Suppl 7 1993 24 27
15. Moskowitz C. Offit K. Straus D. Portlock C. Fludarabine in stage IV low grade non-Hodgkin's lymphoma (LGL): The Memorial Hospital experience Proc ASCO 13 1994 379 (Abstr 1284)
16. Solal-Céligny P. Brice P. Brousse N. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 14 1996 514 519
17. Kay A.C. Saven A. Carrera C.J. Piro L.D. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas J Clin Oncol 10 1992 371 377
18. Hoffman M. Tallman M.S. Hakimian D. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma J Clin Oncol 12 1994 788 792
19. Hickish T. Serafinowski P. Cunningham D. 2′-Chlorodeoxyadenosine: Evaluation of a novel predominately lymphocyte selective agent in lymphoid malignancies Br J Cancer 67 1993 139 143
20. Betticher D.C. Fey M.F. von Rohr A. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias Ann Oncol 5 1994 57 64
21. Saven A. Emanuele S. Kosty M. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent, non-Hodgkin's lymphoma Blood 86 1995 1710 1718
22. Piro L.D. Petroni G. Barcos M. Bolus infusion 2-chlorodeoxyadenosine (2-CdA) as first-line therapy of low-grade non-Hodgkin's lymphoma (NHL): CALGB 9153 Blood 86 Suppl 1 1995 274a (Abstr 1082)
23. Betticher D.C. Zucca E. von Rohr A. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma Ann Oncol 7 8 1996 793 799 (this issue)
24. Burchenal J.H. Murphy M.L. Ellison R.R. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases Blood 8 1953 965 999
25. Ellison R.R. Holland J.F. Weil M. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults Blood 32 1968 507 523
26. Mayer R.J. Davis R.B. Schiffer C.A. Intensive postremission chemotherapy in adults with acute myeloid leukemia N Engl J Med 331 1994 896 903
27. Cheson B.D. The purine analogs - a therapeutic beauty contest J Clin Oncol 10 1992 868 871
28. McLaughlin P. Hagemeister F.B. Swan F. Jr et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma J Clin Oncol 12 1994 575 579
29. McLauglin P. Hagemeister F.B. Romaguerra J.E. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma trial J Clin Oncol 14 1996 1262 1268
30. Zinzani P.L. Bendandi M. Tura S. FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma Eur J Haematol 55 1995 262 266
31. Saven A. Lee T. Kosty M. Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma J Clin Oncol 14 1996 2139 2144
32. Hochster H. Oken M. Bennett J. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first-line therapy of low-grade non-Hodgkin's lymphomas (NHL) - ECOG 1491 Blood 84 Suppl 1 1994 383a (Abstr 1517)
33. Blagosklonny M.V. Schulte T. Nguyen P. Taxol-induced apoptosis and phosphoylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway Cancer Res 56 1996 1851 1854
34. Delia D. Aiello A. Formelli F. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregualted bcl -2 Blood 85 1995 359 367
35. McLaughlin P. Grillo-Lopez A. Czuczman M. Preliminary report on a phase III pivotal trial of the anti-CD20 antibody (MAB) IDEC-C2B8 in patients (PTS) with relapsed low-grade or follicular lymphoma (LG/F NHL) Proc ASCO 15 1996 417 (Abstr 1281)
36. Press O.W. Eary J.F. Appelbaum F.R. Phase II trial of 1311-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas Lancet 346 1995 336 340
37. Kaminski M.S. Zasadny K.R. Francis I.R. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 14 1996 1974 1981